Haemonetics Debt to Equity Ratio 2010-2024 | HAE
Current and historical debt to equity ratio values for Haemonetics (HAE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Haemonetics debt/equity for the three months ending September 30, 2024 was 1.39.
| Haemonetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $1.65B | $0.88B | 1.87 |
| 2024-06-30 | $1.64B | $0.91B | 1.81 |
| 2024-03-31 | $1.24B | $0.96B | 1.29 |
| 2023-12-31 | $1.26B | $0.94B | 1.33 |
| 2023-09-30 | $1.12B | $0.89B | 1.25 |
| 2023-06-30 | $1.10B | $0.87B | 1.27 |
| 2023-03-31 | $1.12B | $0.82B | 1.37 |
| 2022-12-31 | $1.10B | $0.78B | 1.42 |
| 2022-09-30 | $1.14B | $0.73B | 1.56 |
| 2022-06-30 | $1.05B | $0.77B | 1.36 |
| 2022-03-31 | $1.11B | $0.75B | 1.48 |
| 2021-12-31 | $1.10B | $0.73B | 1.51 |
| 2021-09-30 | $1.10B | $0.70B | 1.58 |
| 2021-06-30 | $1.12B | $0.68B | 1.65 |
| 2021-03-31 | $1.09B | $0.73B | 1.49 |
| 2020-12-31 | $0.60B | $0.72B | 0.83 |
| 2020-09-30 | $0.75B | $0.67B | 1.12 |
| 2020-06-30 | $0.83B | $0.61B | 1.36 |
| 2020-03-31 | $0.68B | $0.59B | 1.16 |
| 2019-12-31 | $0.66B | $0.58B | 1.15 |
| 2019-09-30 | $0.61B | $0.58B | 1.04 |
| 2019-06-30 | $0.67B | $0.59B | 1.13 |
| 2019-03-31 | $0.61B | $0.67B | 0.91 |
| 2018-12-31 | $0.59B | $0.64B | 0.91 |
| 2018-09-30 | $0.56B | $0.70B | 0.81 |
| 2018-06-30 | $0.57B | $0.67B | 0.84 |
| 2018-03-31 | $0.49B | $0.75B | 0.64 |
| 2017-12-31 | $0.49B | $0.82B | 0.59 |
| 2017-09-30 | $0.47B | $0.80B | 0.59 |
| 2017-06-30 | $0.48B | $0.77B | 0.62 |
| 2017-03-31 | $0.50B | $0.74B | 0.68 |
| 2016-12-31 | $0.54B | $0.77B | 0.70 |
| 2016-09-30 | $0.59B | $0.75B | 0.78 |
| 2016-06-30 | $0.60B | $0.72B | 0.84 |
| 2016-03-31 | $0.60B | $0.72B | 0.83 |
| 2015-12-31 | $0.62B | $0.72B | 0.86 |
| 2015-09-30 | $0.64B | $0.78B | 0.83 |
| 2015-06-30 | $0.64B | $0.79B | 0.80 |
| 2015-03-31 | $0.66B | $0.83B | 0.80 |
| 2014-12-31 | $0.64B | $0.83B | 0.77 |
| 2014-09-30 | $0.65B | $0.82B | 0.80 |
| 2014-06-30 | $0.66B | $0.82B | 0.81 |
| 2014-03-31 | $0.68B | $0.84B | 0.81 |
| 2013-12-31 | $0.66B | $0.83B | 0.80 |
| 2013-09-30 | $0.69B | $0.80B | 0.86 |
| 2013-06-30 | $0.71B | $0.77B | 0.91 |
| 2013-03-31 | $0.69B | $0.77B | 0.90 |
| 2012-12-31 | $0.70B | $0.78B | 0.89 |
| 2012-09-30 | $0.68B | $0.77B | 0.88 |
| 2012-06-30 | $0.17B | $0.76B | 0.23 |
| 2012-03-31 | $0.18B | $0.73B | 0.24 |
| 2011-12-31 | $0.14B | $0.71B | 0.20 |
| 2011-09-30 | $0.15B | $0.68B | 0.21 |
| 2011-06-30 | $0.14B | $0.71B | 0.20 |
| 2011-03-31 | $0.15B | $0.69B | 0.21 |
| 2010-12-31 | $0.14B | $0.65B | 0.21 |
| 2010-09-30 | $0.14B | $0.59B | 0.24 |
| 2010-06-30 | $0.13B | $0.57B | 0.24 |
| 2010-03-31 | $0.17B | $0.59B | 0.28 |
| 2009-12-31 | $0.13B | $0.57B | 0.23 |
| 2009-09-30 | $0.14B | $0.58B | 0.23 |
| 2009-06-30 | $0.13B | $0.56B | 0.23 |
| 2009-03-31 | $0.11B | $0.54B | 0.20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $4.297B | $1.309B |
| Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.249B | 26.05 |
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Insulet (PODD) | United States | $18.443B | 73.44 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Perrigo (PRGO) | Ireland | $3.830B | 11.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Capricor Therapeutics (CAPR) | United States | $0.847B | 0.00 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |